Global Menopause Market Outlook, 2030

The global menopause market has transformed from a niche segment of women’s health into a broad and rapidly expanding industry, encompassing hormone replacement therapy (HRT), prescription and over-the-counter (OTC) drugs, dietary supplements, personal care and sexual wellness products, and emerging digital health solutions. This growth is fueled by increasing demand arising from demographic shifts, particularly the aging global population and the rising proportion of women aged 50 and above, which has significantly increased the absolute number of women entering menopause. Urbanization further amplifies demand, as women in metropolitan areas have greater access to healthcare services, information, and disposable income, driving adoption of both clinical and consumer-focused products. According to a menopause survey of women aged 35 and above conducted in January 2024 by AARP, a U.S.-based nonprofit organization, around 90% of women experience menopausal symptoms that affected their lives as well as work, along with other day-to-day activities. Socio-cultural changes, including the normalization of menopause discussions through media, advocacy groups, and influencers, have reduced stigma, encouraging women to seek treatment and self-care solutions. Marketing and promotion strategies in the industry are highly omnichannel, combining physician education and outreach for prescription uptake with direct-to-consumer advertising via social media, telemedicine platforms, and wellness-focused retail channels. However, this expansion has also brought concerns over “menowashing,” where everyday products are rebranded as menopause-specific solutions without solid evidence, prompting increased regulatory oversight. Authorities such as the U.S. FDA and FTC, as well as the UK’s ASA, enforce strict guidelines on advertising claims, requiring scientific substantiation and prohibiting misleading medical claims for supplements and non-licensed products. In the prescription drug space, stringent regulatory pathways govern safety, efficacy, and post-market surveillance, especially for hormone-based therapies. Policies on reimbursement and healthcare access also play a critical role, influencing treatment uptake, particularly in lower-income or rural populations.

According to the research report “Global Menopause Market Outlook, 2030” published by Bonafide Research, the global Menopause market is projected to reach market size of USD 25.05 Billion by 2030 increasing from USD 17.45 Billion in 2024, growing with 6.35% CAGR by 2025-30.Medically, advances in hormone replacement therapy (HRT), non-hormonal drugs, and nutraceuticals are expanding the range of treatment options. For instance, selective estrogen receptor modulators (SERMs) and neurokinin-3 receptor antagonists offer alternatives for women who cannot take traditional HRT, opening new market segments. Technology is another growth enabler, with digital health platforms and menopause-focused apps offering teleconsultations, personalized symptom tracking, and AI-driven treatment recommendations, bridging the gap between patients and providers. Culturally, the market benefits from a growing openness in discussing menopause, supported by celebrity advocacy, corporate wellness programs, and global campaigns such as “World Menopause Day,” which boost awareness and normalize seeking help. This social shift is particularly important in breaking the silence in regions where menopause has been a taboo subject, creating untapped market potential. The regulatory front, stricter safety and labeling requirements, while posing compliance challenges, also serve as an opportunity for reputable brands to build trust and differentiate themselves in a crowded market. The integration of menopause care into preventive healthcare, linking it with bone health, cardiovascular health, and cognitive wellness, which creates cross-sector collaboration between pharmaceuticals, nutrition, and wellness industries. Supporting events and industry movements are also shaping growth—venture capital is increasingly flowing into femtech startups targeting menopause, signaling investor confidence, and healthcare conferences are dedicating more focus to midlife women’s health, fostering innovation and collaboration. In September 2024, Theramex announced the initial commercial sale of Yselty (linzagolix) in Germany. This treatment for uterine fibroids provides a vital option for females facing significant unmet medical needs. This achievement enhances the available resources in the battle against uterine fibroids, offering females a crucial solution for managing moderate-to-severe symptoms associated with this condition.

Market Drivers

• Growing Awareness and Education on Menopause Health: One of the strongest drivers in the global menopause market is the increasing awareness about menopause-related symptoms and health implications. Governments, healthcare organizations, and advocacy groups are actively conducting campaigns to educate women about perimenopause, menopause, and postmenopause care. Social media platforms, online forums, and virtual health consultations are making information more accessible, reducing the stigma around discussing menopause. This heightened awareness encourages early diagnosis and proactive management, which in turn boosts demand for supplements, hormone replacement therapy (HRT), non-hormonal treatments, and lifestyle-based interventions.
• Rising Aging Female Population Worldwide: The growing demographic of women aged 45 and above is a critical market driver. With global life expectancy increasing, a larger proportion of women are experiencing menopause and living for decades beyond it, leading to sustained healthcare needs. The UN projects that by 2050, nearly 1.6 billion women will be over the age of 50, significantly expanding the potential consumer base for menopause-related products and services. This demographic shift also increases the prevalence of associated health issues such as osteoporosis, cardiovascular conditions, and urogenital disorders, creating a broader demand for preventive and therapeutic solutions.

Market Challenges

• Side Effects and Risks of Hormone-Based Therapies: Hormone replacement therapy, a widely used treatment for menopause symptoms, is often associated with risks such as increased chances of blood clots, stroke, and certain cancers, depending on the dosage and duration. These safety concerns, supported by medical studies, create hesitation among both healthcare providers and patients, leading to a slower adoption rate in some regions. Regulatory warnings and the need for continuous monitoring further complicate treatment uptake, limiting market growth potential for certain therapeutic categories.
• Unequal Access and Affordability Issues: Access to menopause care remains uneven globally, with disparities between urban and rural areas, and between high-income and low-income countries. In many developing economies, menopause management is still underdiagnosed or overlooked due to cultural stigma, lack of trained specialists, and limited healthcare infrastructure. Moreover, advanced therapies and branded supplements are often expensive, making them unaffordable for large sections of the population. These barriers restrict market penetration and slow overall industry growth.

Market Trends

• Shift Toward Natural and Non-Hormonal Solutions: A notable trend is the growing demand for natural, plant-based, and non-hormonal treatments such as phytoestrogen supplements, herbal remedies, and functional foods. Women are increasingly seeking safer, long-term symptom management options without the potential risks of synthetic hormones. This has encouraged innovation in botanical extracts, nutraceutical blends, and personalized supplement programs, often marketed with a focus on holistic wellness and lifestyle integration.
• Digital Health Integration for Menopause Care: The rise of telemedicine, mobile health apps, and wearable technology is reshaping menopause management. Digital platforms now offer symptom tracking, personalized treatment recommendations, mental health support, and access to specialized menopause clinics virtually. Some solutions integrate AI-driven analytics to optimize treatment plans based on patient data. This trend not only improves access to care but also encourages continuous engagement and adherence to treatment, making menopause management more convenient and data-driven.

Dietary supplements are the largest treatment type in the global menopause industry because they offer a natural, accessible, and non-prescription alternative for managing menopause symptoms, aligning with rising consumer preference for holistic health solutions.

The dominance of dietary supplements in the global menopause industry is driven by a growing preference among women for natural, safe, and easily accessible solutions to manage the wide range of symptoms associated with menopause, such as hot flashes, night sweats, mood swings, bone density loss, and hormonal imbalances. Unlike hormone replacement therapy (HRT), which requires a prescription and comes with concerns about potential side effects such as increased risks of certain cancers and cardiovascular issues, dietary supplements are perceived as lower-risk, over-the-counter options that can be incorporated seamlessly into daily routines. These supplements, which often include ingredients like soy isoflavones, black cohosh, red clover, calcium, vitamin D, and omega-3 fatty acids, appeal to the growing segment of women who seek plant-based or herbal alternatives for symptom relief. The shift towards preventive healthcare and the increased focus on overall wellness has further boosted demand, as supplements are often marketed not just for symptom control, but also for supporting long-term health in areas such as bone strength, heart health, and cognitive function. Accessibility plays a key role in this trend, with dietary supplements available across multiple retail formats including pharmacies, supermarkets, online stores, and direct-to-consumer platforms, making them convenient for women in both developed and emerging markets. Additionally, the booming nutraceutical and functional food industry has created greater awareness through aggressive marketing, celebrity endorsements, and educational campaigns, helping normalize supplement use during menopause.

The menopause stage type is the largest in the global menopause industry because it represents the peak period of symptom severity and healthcare intervention, driving the highest demand for treatments and support solutions.

The menopause stage type dominates the global menopause industry primarily because it is the phase during which women experience the most intense and disruptive symptoms, prompting greater reliance on medical, nutritional, and lifestyle interventions. Menopause, defined as the permanent cessation of menstruation for 12 consecutive months, typically occurs between the ages of 45 and 55 and is accompanied by a significant decline in estrogen and progesterone production. This hormonal shift triggers a wide array of physical and emotional changes, including hot flashes, night sweats, mood swings, sleep disturbances, vaginal dryness, reduced libido, and accelerated bone density loss. The severity and frequency of these symptoms during this stage are often more pronounced compared to the perimenopause or postmenopause phases, leading women to actively seek effective treatment options. As a result, the demand for therapies ranging from hormone replacement therapy (HRT) and dietary supplements to non-hormonal prescription drugs and alternative remedies peaks during this period. Additionally, menopause is a clear, diagnosable stage, unlike perimenopause, which can have vague or fluctuating symptoms, making targeted marketing and product positioning easier for industry players. Healthcare providers are also more proactive during menopause in recommending treatments and lifestyle modifications, further boosting market demand. Culturally and socially, awareness campaigns and workplace wellness initiatives increasingly highlight menopause as a critical women’s health issue, encouraging more women to address their symptoms rather than endure them in silence.

The oral route of administration is the largest in the global menopause industry because it offers convenience, ease of use, precise dosing, and wide availability across both prescription and over-the-counter treatment options.

The oral route of administration dominates the global menopause industry largely due to its unmatched convenience, familiarity, and accessibility, making it the preferred choice for millions of women managing menopause symptoms. Whether in the form of hormone replacement therapy (HRT) tablets, dietary supplements, or non-hormonal medications, oral products are simple to use, require no special application techniques, and allow for precise and consistent dosing, which is essential for effective symptom control. For many women, taking a pill or capsule fits seamlessly into their daily routine, ensuring higher adherence rates compared to topical creams, gels, patches, or injectable treatments. Oral menopause products are also widely available in various strengths and formulations, ranging from prescription-based HRT options to over-the-counter herbal supplements containing ingredients such as soy isoflavones, black cohosh, and red clover. This versatility appeals to a broad demographic, from women seeking medically supervised hormone therapy to those preferring natural, plant-based alternatives. Furthermore, oral medications benefit from extensive manufacturing infrastructure and established pharmaceutical supply chains, allowing for global distribution through retail pharmacies, supermarkets, e-commerce platforms, and direct-to-consumer brands. The cost-effectiveness of oral treatments compared to certain transdermal or injectable alternatives also contributes to their popularity, particularly in emerging markets where affordability plays a crucial role in treatment decisions. In addition, the oral route facilitates combination formulations, enabling products to address multiple menopause-related issues such as bone health, cardiovascular support, and mood stabilization in a single dose.

Hospitals are the largest end-user type in the global menopause industry because they serve as primary centers for comprehensive diagnosis, specialized treatment, and multidisciplinary care for women experiencing menopause-related health issues.

Hospitals hold the largest share in the global menopause industry because they provide the most comprehensive and specialized care for women navigating the physical and psychological challenges of menopause. As menopause often involves complex hormonal changes and associated health risks such as osteoporosis, cardiovascular disease, and mental health issues many women seek hospital-based services for accurate diagnosis, individualized treatment plans, and continuous monitoring. Hospitals offer access to experienced gynecologists, endocrinologists, dietitians, and mental health professionals, enabling a multidisciplinary approach that addresses both symptom relief and long-term wellness. Advanced diagnostic tools available in hospital settings, such as bone density scans, blood hormone level testing, and cardiovascular assessments, allow for precise identification of menopause-related conditions, which in turn leads to more effective, tailored treatments. In many cases, hospitals are also the preferred setting for initiating hormone replacement therapy (HRT), as medical supervision is critical for monitoring dosage, managing side effects, and adjusting treatment according to patient response. Beyond clinical care, hospitals are often equipped with patient education programs, counseling services, and support groups that help women better understand and manage menopause. The credibility and trust associated with hospital-based care make women more likely to choose these facilities for treatment, especially when symptoms are severe or when coexisting health conditions require coordinated care. dditionally, hospitals often serve as referral centers for complex or high-risk menopause cases that cannot be adequately addressed in smaller clinics or retail healthcare settings.

Retail pharmacies are the largest distribution channel in the global menopause industry because they offer convenient access, a wide product range, and trusted guidance for both prescription and over-the-counter menopause treatments.

Retail pharmacies dominate the distribution channel landscape in the global menopause industry due to their unique combination of accessibility, product variety, and professional guidance, making them the most preferred source for women seeking menopause-related solutions. These outlets serve as the primary point of purchase for a wide spectrum of products, including prescription hormone replacement therapies (HRT), over-the-counter dietary supplements, herbal remedies, and non-hormonal medications for symptom relief. Their widespread presence in urban, suburban, and even rural areas ensures that women can easily access menopause treatments without the need for hospital visits, which is especially valuable for those managing mild to moderate symptoms. In addition to physical convenience, retail pharmacies provide personalized, face-to-face consultations with licensed pharmacists who can advise on product selection, dosage, potential interactions, and side effects offering a level of trust and reassurance that online channels may lack. Pharmacies also cater to varying consumer preferences and budgets by stocking multiple brands, formulations, and package sizes, from affordable generics to premium products. In many countries, regulatory frameworks allow a significant portion of menopause-related products, especially dietary supplements and certain non-hormonal options, to be sold without a prescription, further boosting retail pharmacy sales. Moreover, retail chains often run targeted promotions, loyalty programs, and in-store health awareness campaigns that encourage women to proactively address menopause symptoms. The role of retail pharmacies has expanded beyond dispensing medications to include health screenings, bone density checks, and wellness consultations, positioning them as integral community health hubs for midlife women.

North America is the largest market in the global menopause industry because of its high awareness, advanced healthcare infrastructure, strong purchasing power, and widespread access to diverse treatment options.

North America leads the global menopause industry primarily due to its combination of high awareness levels, advanced healthcare systems, and strong economic capacity, which collectively create an environment highly conducive to the adoption of menopause treatments and wellness solutions. The region has one of the highest proportions of women in the 45–60 age group, a demographic that experiences menopause and actively seeks solutions to manage its symptoms. Widespread health literacy and the destigmatization of menopause in public discourse encourage women to openly address their needs, resulting in higher diagnosis rates and proactive treatment adoption. The healthcare infrastructure in North America, particularly in the United States and Canada, is well-equipped with specialized gynecologists, endocrinologists, and wellness practitioners, enabling women to access a full spectrum of care from hormone replacement therapy (HRT) to advanced non-hormonal treatments, dietary supplements, and alternative therapies. Furthermore, a mature pharmaceutical and nutraceutical industry supports the continuous development and marketing of innovative products tailored to menopause symptom management, including personalized therapies and bioidentical hormones. High disposable incomes and comprehensive insurance coverage for certain menopause-related treatments further boost market demand, as women are able to invest in premium, specialized products. Retail pharmacies, specialty clinics, and online platforms in the region also offer wide product availability, from over-the-counter supplements to prescription drugs, making treatments accessible both in-store and through digital channels.

• In March 2025, Dr. Reddy’s Laboratories Ltd. and Alvotech announced that the FDA has accepted a 351(k) Biologic License Application (BLA) submission for AVT03, a proposed biosimilar of Prolia® (denosumab) and Xgeva® (denosumab), developed by Alvotech.
• In January 2024, Bayer AG announced the successful last trial of a menopausal relief drug. The purpose of this drug is to improve sleep and ease hot flashes in postmenopausal women.
• In December 2024, Theramex acquired products such as Duphaston and Femoston from Viatris in Europe (ex-UK). This product acquisition strengthened the company’s menopause portfolio, helping it offer a wide range of treatments for women across Europe.
• In May 2023- The Food and Drug Administration announced that it had approved a new drug to treat moderate to severe hot flashes caused by menopause. It could provide respite to millions of women who do not wish to undergo hormone therapy to treat their symptoms. Astellas stated that the tablets containing fezolinetant under Veozah could be available in pharmacies within three weeks.
• In March 2023, Theramex entered a licensing partnership with Radius Health, Inc. This agreement aims to help distribute and commercialize ELADYNOS (abaloparatide) for the treatment of osteoporosis in postmenopausal women in the European Economic Area, Brazil, the UK, and Australia.
• In March 2023- Aptorum Group Limited, a clinical-stage biopharmaceutical firm dedicated to the development of novel therapeutics to address unmet medical needs, unveiled the exciting commercial launch of NativusWell®, a new dietary supplement supporting women's health throughout the Menopause cycles aimed at the China market.
• In May 2023, Astellas Pharma Inc. obtained approval from the FDA for VEOZAH, a groundbreaking nonhormonal neurokinin 3 (NK3) receptor antagonist. This marks the first-of-its-kind approval for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.
• In March 2023, Amyris, Inc. acquired MenoLabs, LLC, a company specializing in menopause treatment and research in this field. This strategic acquisition is poised to facilitate the expansion of Amyris, Inc.'s product portfolio in the realm of menopause treatments. Show more